Top in allergy/asthma: Cannabis harmful with asthma; in-flight allergic reactions are rare
Click Here to Manage Email Alerts
Patients who use cannabis and experience acute asthma attacks had greater risks for mortality and mechanical ventilation, researchers reported.
However, there were no differences between users and nonusers regarding their risks for pneumonia or sepsis, they said.
It was the top story in allergy/asthma last week.
Another top story was about a study that showed 2% to 3% of in-flight medical events are due to allergic reactions, with approximately 0.7 reactions per million passengers. In a perspective, Christopher M. Warren, PhD, director of population research at the Center for Food Allergy & Asthma Research at Northwestern University Feinberg School of Medicine, offered some helpful context to the findings.
Read these and more top stories in allergy/asthma below:
Cannabis use may increase mortality, morbidity from acute asthma exacerbations
Cannabis use may increase mortality and morbidity in patients with acute asthma exacerbations, according to a poster presented at the CHEST Annual Meeting. Read more.
Allergic reactions rare during commercial flights
Approximately 2% to 3% of in-flight medical events are due to allergic reactions, with approximately 0.7 reactions per million passengers, according to a review published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
EAACI updates guidelines for diagnosing IgE-mediated food allergy
The European Academy of Allergy and Clinical Immunology has updated its EAACI Guidelines on Food Allergy Diagnosis, targeting patients with IgE-mediated food allergies. Read more.
FDA schedules Type A meeting to discuss epinephrine nasal spray
The FDA has scheduled a Type A meeting with ARS Pharma to discuss the complete response letter that the FDA previously issued to the company about its new drug application for its neffy epinephrine nasal spray. Read more.
Patients with well-controlled chronic urticaria may halt omalizumab treatment
Some patients who use omalizumab to treat their chronic urticaria may discontinue its use to reveal disease remission and avoid drug exposure, according to a study. Read more.